The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer

被引:16
作者
Albisinni, S. [1 ]
Moussa, I. [1 ]
Aoun, F. [2 ]
Quackels, T. [1 ]
Assenmacher, G. [2 ]
Peltier, A. [2 ]
Roumeguere, T. [1 ]
机构
[1] Univ Libre Bruxelles, Hop Erasme, Dept Urol, Univ Clin Brussels, Route Lennik 808, Brussels, Belgium
[2] Univ Libre Bruxelles, Jules Bordet Inst, Urol Dept, Brussels, Belgium
来源
PROGRES EN UROLOGIE | 2019年 / 29卷 / 05期
关键词
Bladder cancer; Inflammation; Recurrence; Survival; TO-LYMPHOCYTE RATIO; CARCINOMA; SURVIVAL;
D O I
10.1016/j.purol.2019.02.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. The clinical impact of inflammatory biomarkers has been evaluated in urothelial bladder cancer. However, data are limited to preoperative values and there is paucity of evidence of the role of postoperative measurement of those biomarkers. The aim of the current study was to determine the association of inflammatory biomarkers as neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), hemoglobin to platelet ratio (HPR) and C-reactive protein (CRP), before and after radical cystectomy, with recurrence and survival of bladder cancer. Material and methods. We prospectively evaluated 134 patients undergoing radical cystectomy for invasive bladder cancer between January 2013 and January 2018. The inflammatory biomarkers were measured 10 days before surgery and at 1, 6 and 12 months postoperatively. Kaplan Meier curves and Cox proportional hazards and logistic regression models were used to evaluate the association between the different inflammatory biomarkers and recurrence free survival (RFS), cancer specific survival (CSS) and overall survival (OS). Results. The median follow-up time was 21.1 months (5-37 mo). On multivariate analysis, preoperative NLR > 3.88 was associated to locally-advanced disease (> pT3) and NLR > 3.88 and HPR < 0.039 were significantly associated to node positive disease. Postoperative NLR at 3 months > 4.68 (HR: 2.37, 95% CI: 1.08-4.47, P=0.03) was associated with a reduced RFS. A postoperative NLR at 3 months > 4.68 (P= 0.04) and a postoperative HPR at 3 months < 0.029 (P= 0.001) were associated with a significant reduction in CSS and OS. Conclusion. Postoperative NLR and HPR at 3 months appear to be closely associated with RFS, CSS and OS. Further studies are needed on these postoperative markers to establish the potential impact of these inflammatory biomarkers on a tailored therapeutic approach for each patient. Level of evidence. 3. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:270 / 281
页数:12
相关论文
共 21 条
  • [1] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
    Antoni, Sebastien
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Znaor, Ariana
    Jemal, Ahmedin
    Bray, Freddie
    [J]. EUROPEAN UROLOGY, 2017, 71 (01) : 96 - 108
  • [2] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [3] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [4] Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
    Cumberbatch, Marcus George Kwesi
    Jubber, Ibrahim
    Black, Peter C.
    Esperto, Francesco
    Figueroa, Jonine D.
    Kamat, Ashish M.
    Kiemeney, Lambertus
    Lotan, Yair
    Pang, Karl
    Silverman, Debra T.
    Znaor, Ariana
    Catto, James W. F.
    [J]. EUROPEAN UROLOGY, 2018, 74 (06) : 784 - 795
  • [5] Can Neutrophil-Lymphocyte Ratio and Lymph Node Density Be Used as Prognostic Factors in Patients Undergoing Radical Cystectomy?
    Demirtas, Abdullah
    Sabur, Volkan
    Akinsal, Emre Can
    Demirci, Deniz
    Ekmekcioglu, Oguz
    Gulmez, Ibrahim
    Tatlisen, Atila
    [J]. SCIENTIFIC WORLD JOURNAL, 2013,
  • [6] A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer
    El Rassy, Elie
    Bakouny, Ziad
    Aoun, Fouad
    Haddad, Fadi G.
    Sleilaty, Ghassan
    Assi, Tarek
    Kattan, Joseph
    [J]. IMMUNOTHERAPY, 2018, 10 (08) : 657 - 663
  • [7] The Role of Inflammation in Bladder Cancer
    Gakis, Georgios
    [J]. INFLAMMATION AND CANCER, 2014, 816 : 183 - 196
  • [8] Immunity, Inflammation, and Cancer
    Grivennikov, Sergei I.
    Greten, Florian R.
    Karin, Michael
    [J]. CELL, 2010, 140 (06) : 883 - 899
  • [9] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
    Heng, Daniel Y. C.
    Xie, Wanling
    Regan, Meredith M.
    Warren, Mark A.
    Golshayan, Ali Reza
    Sahi, Chakshu
    Eigl, Bernhard J.
    Ruether, J. Dean
    Cheng, Tina
    North, Scott
    Venner, Peter
    Knox, Jennifer J.
    Chi, Kim N.
    Kollmannsberger, Christian
    McDermott, David F.
    Oh, William K.
    Atkins, Michael B.
    Bukowski, Ronald M.
    Rini, Brian I.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5794 - 5799
  • [10] Jimenez MP, 2016, EUR UROL SUPPL, V15, DOI [10.1016/S1569-9056(16)61045-X, DOI 10.1016/S1569-9056(16)61045-X]